Drug Trial Radar · NCT07266831
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
570
Planned (sponsor's estimate)
Start
Dec 18, 2025
Primary completion
Feb 1, 2029
Study completion Dec 18, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to learn: 1) If the study ART works as well as a standard ART to treat HIV-1, and 2) About the safety of the study ART and if people tolerate it compared to a standard ART.
Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions
ISLDrug
ISL 2 x 1 mg oral capsules administered qw for 96 weeks
ULODrug
ULO 2 x 100 mg oral tablets administered qw for 96 weeks
BIC/FTC/TAFDrug
BIC/FTC/TAF 50/200/25 mg oral tablet administered qd for 96 weeks
Placebo for BIC/FTC/TAFDrug
BIC/FTC/TAF-matching placebo oral tablet administered qd for 96 weeks
Placebo to ISL/ULODrug
ISL/ULO-matching placebo oral tablets administered qw for 96 weeks
ISL/ULODrug
ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Percentage of Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL at Week 24Time frame: Week 24
- Phase 2: Percentage of Participants Who Experience an Adverse Event (AE) at Week 24Time frame: Week 24
- Phase 2: Percentage of Participants Who Discontinue Study Intervention Due to an AE at Week 24Time frame: Week 24
- Phase 3: Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48Time frame: Week 48
- Phase 3: Percentage of Participants Who Experience an AE at Week 48Time frame: Week 48
- Phase 3: Percentage of Participants Who Discontinue Study Intervention Due to an AE at Week 48Time frame: Week 48
Locations
56 sites in 9 countries. Site status is shown where the registry gives one.
Ruane Clinical Research Group, Inc. ( Site 1513)
Los Angeles, California · Recruiting
Vivent Health ( Site 1519)
Denver, Colorado · Recruiting
Whitman-Walker Institute ( Site 1538)
Washington D.C., District of Columbia · Recruiting
Midway Immunology and Research Center ( Site 1503)
Ft. Pierce, Florida · Recruiting
CAN Community Health- Miami Gardens ( Site 1549)
Miami Gardens, Florida · Recruiting
Orlando Immunology Center ( Site 1501)
Orlando, Florida · Recruiting
CAN Community Health ( Site 1510)
Sarasota, Florida · Recruiting
Triple O Research Institute ( Site 1505)
West Palm Beach, Florida · Recruiting
Metro Infectious Diseases Consultants L.L.C. ( Site 1509)
Decatur, Georgia · Recruiting
Mercer university, Department of internal medicine-Clinical Research ( Site 1512)
Macon, Georgia · Recruiting
Rush University Medical Center-Infectious Disease ( Site 1522)
Chicago, Illinois · Recruiting
Henry Ford Hospital ( Site 1535)
Detroit, Michigan · Recruiting
KC CARE Health Center ( Site 1506)
Kansas City, Missouri · Recruiting
ID Care ( Site 1507)
Hillsborough, New Jersey · Recruiting
Atrium Health Infectious Disease Kenilworth - Charlotte ( Site 1533)
Charlotte, North Carolina · Recruiting
Regional Center for Infectious Diseases ( Site 1516)
Greensboro, North Carolina · Recruiting
The Ohio State University ( Site 1536)
Columbus, Ohio · Recruiting
University of Pennsylvania Perelman School of Medicine ( Site 1508)
Philadelphia, Pennsylvania · Recruiting
Saint Hope Foundation, Inc. ( Site 1504)
Bellaire, Texas · Recruiting
Prism Health North Texas, Oak Cliff Health Center ( Site 1514)
Dallas, Texas · Recruiting
North Texas Infectious Diseases Consultants ( Site 1500)
Dallas, Texas · Active not recruiting
Texas Center for Infectious Disease Associates ( Site 1502)
Fort Worth, Texas · Recruiting
DCOL Center for Clinical Research ( Site 1511)
Longview, Texas · Recruiting
Harborview Medical Center ( Site 1526)
Seattle, Washington · Recruiting
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 3102)
Caba, Buenos Aires, Argentina · Recruiting
Fundación Huesped ( Site 3100)
CABA, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Mar del Plata ( Site 3103)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Fundación IDEAA ( Site 3101)
Buenos Aires, Buenos Aires F.D., Argentina · Recruiting
Instituto CAICI SRL ( Site 3106)
Rosario, Santa Fe Province, Argentina · Recruiting
Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 3105)
San Miguel de Tucumán, Tucumán Province, Argentina · Recruiting
Spectrum Health ( Site 3307)
Vancouver, British Columbia, Canada · Completed
Gestion clinique médicale l'Actuel ( Site 3303)
Montreal, Quebec, Canada · Recruiting
Biomedica Research Group ( Site 4201)
Santiago, Region M. de Santiago, Chile · Recruiting
Clínica Universidad de Los Andes ( Site 4207)
Santiago, Region M. de Santiago, Chile · Recruiting
Espacio Eme ( Site 4202)
Santiago, Region M. de Santiago, Chile · Active not recruiting
Bordeaux University Hospital - Pellegrin ( Site 3605)
Bordeaux, Gironde, France · Recruiting
Centre Hospitalier Universitaire de Toulouse - Hôpital Purpan ( Site 3608)
Toulouse, Haute-Garonne, France · Recruiting
Hôpital Avicenne ( Site 3602)
Bobigny, Île-de-France Region, France · Recruiting
Hôpital Saint-Louis ( Site 3600)
Paris, Île-de-France Region, France · Recruiting
Hôpital Bichat - Claude-Bernard ( Site 3601)
Paris, Île-de-France Region, France · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.